Table 3 presents the amount of care consumption and mean costs per patient during two and three years of follow-up.
The health outcomes of these patients are presented in Table 2 and the amount of care consumption and mean costs per patient during two and three years of follow-up are presented in Table 3.
They include discharges, total costs, and mean costs per discharge for selected PPCs during the period before implementation of the demonstration program.
Resource use measures computed for each patient included: a) total hospital costs incurred during the ICU stay, b) mean costs per ICU day, c) total costs incurred from ICU admission to hospital discharge, d) costs per day during ICU stay for specific cost categories (pharmacy, lab, imaging, respiratory therapy), e) ICU and total hospital (from ICU admission) length of stay (LOS).
Results of the cost analyses are presented by reporting mean volumes, total costs, mean costs per patient per strategy for the on-demand group and the planned group for resource utilization during the index admission, and follow-up (Table 2).
I mean cost is important.
The mean cost during the ICU stay per patient increased most (€3003).
Patients in the upper 5% of the cost distribution incurred mean costs of $117,193 ±55,5500 during 1 year of follow-up compared to $17,086 ±17,7922 for the lower-cost group.
The mean costs of INR controls during the first three months, the first year and during the second year of treatment were SEK 6,811, SEK 16,244 and SEK 8,904 respectively.
